skip to Main Content

Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation

Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation.


Back To Top